You are currently viewing a new version of our website. To view the old version click .

811 Results Found

  • Review
  • Open Access
5 Citations
3,831 Views
14 Pages

The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors

  • Konstantinos Evmorfopoulos,
  • Konstantinos Marsitopoulos,
  • Raphael Karachalios,
  • Athanasios Karathanasis,
  • Konstantinos Dimitropoulos,
  • Vassilios Tzortzis,
  • Ioannis Zachos and
  • Panagiotis J. Vlachostergios

19 January 2024

Testicular germ cell tumors (TGCTs) are cancers with very good prognosis, even in the metastatic setting, with high curative potential mainly attributed to the introduction of cisplatin-based chemotherapy. However, approximately 15% of the patients d...

  • Review
  • Open Access
2 Citations
3,203 Views
11 Pages

20 August 2023

Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing nov...

  • Case Report
  • Open Access
1,719 Views
6 Pages

29 November 2024

Background and Clinical Significance: Tumor lysis syndrome (TLS) is a rare occurrence in patients treated with venetoclax mono- or combination therapy, and clear protocols guiding TLS prophylaxis are lacking. Case Presentation: We present a 53-year-o...

  • Article
  • Open Access
6 Citations
3,328 Views
20 Pages

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

  • Sarah Jannier,
  • Véronique Kemmel,
  • Consuelo Sebastia Sancho,
  • Agathe Chammas,
  • Amelia-Naomie Sabo,
  • Erwan Pencreach,
  • Françoise Farace,
  • Marie Pierre Chenard,
  • Benoit Lhermitte and
  • Birgit Geoerger
  • + 11 authors

20 October 2020

Hypoxic environment is a prognostic factor linked in pediatric cancers to a worse outcome, favoring tumor progression and resistance to treatments. The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can...

  • Article
  • Open Access
1,001 Views
14 Pages

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors

  • Jessica Boklan,
  • Anne-Marie Langevin,
  • Kevin Bielamowicz,
  • Kathleen Neville,
  • Tanya Trippett,
  • Valerie Brown,
  • Steven G. DuBois,
  • Francis Eshun,
  • Jonathan Gelfond and
  • Ativ Zomet
  • + 2 authors

6 September 2025

Background: Novel therapies are needed for children, adolescents, and young adults with relapse/refractory leukemia or solid tumors. The proteasome inhibitor carfilzomib has demonstrated pre-clinical activity against several pediatric malignancies wh...

  • Article
  • Open Access
1,917 Views
11 Pages

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

  • Takuya Azechi,
  • Yutaka Fukaya,
  • Chika Nitani,
  • Junichi Hara,
  • Hiroshi Kawamoto,
  • Tomoaki Taguchi,
  • Kenichi Yoshimura,
  • Akihiro Sato,
  • Naoko Hattori and
  • Toshikazu Ushijima
  • + 1 author

14 November 2024

Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this...

  • Article
  • Open Access
8 Citations
3,177 Views
17 Pages

Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI

  • Hossein Taghizadeh,
  • Matthias Unseld,
  • Martina Spalt,
  • Robert M. Mader,
  • Leonhard Müllauer,
  • Thorsten Fuereder,
  • Markus Raderer,
  • Maria Sibilia,
  • Mir Alireza Hoda and
  • Stefanie Aust
  • + 6 authors

23 October 2020

Advanced therapy-refractory solid tumors bear a dismal prognosis and constitute a major challenge in offering effective treatment strategies. In this real-world retrospective analysis of our precision medicine platform MONDTI, we describe the molecul...

  • Article
  • Open Access
1,313 Views
18 Pages

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers

  • Gentry G. King,
  • Kelsey K. Baker,
  • Andrew L. Coveler,
  • William P. Harris,
  • Stacey A. Cohen,
  • Veena Shankaran,
  • David B. Zhen,
  • Rachael A. Safyan,
  • Hannah H. Lee and
  • Annie Alidina
  • + 13 authors

30 May 2025

Background: The epidermal growth factor receptor (EGFR) is overactive in many tumors. This phase I trial evaluated the safety and preliminary efficacy of afatinib plus capecitabine in refractory pancreatic ductal adenocarcinoma (PDA), biliary tract c...

  • Article
  • Open Access
5 Citations
2,666 Views
12 Pages

Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors

  • Chien-Chang Kao,
  • Ching-Liang Ho,
  • Ming-Hsin Yang,
  • Yi-Ta Tsai,
  • Shu-Yu Liu,
  • Ping-Ying Chang,
  • Yi-Ying Wu,
  • Jia-Hong Chen,
  • Tzu-Chuan Huang and
  • Ren-Hua Yehn
  • + 4 authors

14 April 2022

Background: Combination therapy with the administration of GW5074 and sorafenib significantly induced necrotic death in various cancer cells in vivo, as well as prolonging the survival of an animal disease model due to significant suppression of the...

  • Article
  • Open Access
2,130 Views
18 Pages

Background/Objectives: Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or refractory brain tumors...

  • Article
  • Open Access
1,481 Views
10 Pages

Outcomes and Predictive Factors of I-125 Plaque Therapy for Refractory Retinoblastoma

  • Yacoub A. Yousef,
  • Farah Halawa,
  • Mona Mohammad,
  • Lama Al-Fahoum,
  • Rama Soudi,
  • Mustafa Mehyar,
  • Reem AlJabari,
  • Hadeel Halalsheh,
  • Ibrahim AlNawaiseh and
  • Imad Jaradat

6 March 2025

Objective: This study aimed to evaluate the outcomes and predictive factors of I-125 radioactive plaque therapy for recurrent and refractory retinoblastoma (Rb) cases that failed primary systemic chemotherapy and focal therapies. Methods: A retrospec...

  • Article
  • Open Access
7 Citations
3,298 Views
10 Pages

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

  • Arif Manji,
  • Yvan Samson,
  • Rebecca J. Deyell,
  • Donna L. Johnston,
  • Victor A. Lewis,
  • Alexandra P. Zorzi,
  • Jason N. Berman,
  • Kathy Brodeur-Robb,
  • Ellen Morrison and
  • Lynn Kee
  • + 4 authors

17 June 2022

Oral metronomic topotecan represents a novel approach to chemotherapy delivery which, in preclinical models, may work synergistically with pazopanib in targeting angiogenesis. A phase I and pharmacokinetic (PK) study of this combination was performed...

  • Review
  • Open Access
11 Citations
3,795 Views
28 Pages

Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints

  • Dharmindra Dulal,
  • Andrew Boring,
  • David Terrero,
  • Tiffany Johnson,
  • Amit K. Tiwari and
  • Dayanidhi Raman

16 May 2023

Physiologically, well known or traditional immune checkpoints (ICs), such as CTLA-4 and PD-1, are in place to promote tolerance to self-antigens and prevent generation of autoimmunity. In cancer, the ICs are effectively engaged by the tumor cells or...

  • Review
  • Open Access
134 Citations
9,147 Views
26 Pages

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma

  • Jose J.G. Marin,
  • Rocio I.R. Macias,
  • Maria J. Monte,
  • Marta R. Romero,
  • Maitane Asensio,
  • Anabel Sanchez-Martin,
  • Candela Cives-Losada,
  • Alvaro G. Temprano,
  • Ricardo Espinosa-Escudero and
  • Maria Reviejo
  • + 2 authors

23 June 2020

The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pha...

  • Feature Paper
  • Review
  • Open Access
47 Citations
6,267 Views
29 Pages

Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma

  • Jose J. G. Marin,
  • Laura Perez-Silva,
  • Rocio I. R. Macias,
  • Maitane Asensio,
  • Ana Peleteiro-Vigil,
  • Anabel Sanchez-Martin,
  • Candela Cives-Losada,
  • Paula Sanchon-Sanchez,
  • Beatriz Sanchez De Blas and
  • Elisa Herraez
  • + 2 authors

30 July 2020

Gastric adenocarcinoma (GAC) is the most common histological type of gastric cancer, the fifth according to the frequency and the third among the deadliest cancers. GAC high mortality is due to a combination of factors, such as silent evolution, late...

  • Review
  • Open Access
8 Citations
5,556 Views
17 Pages

Treatment Modalities for Refractory-Recurrent Tenosynovial Giant Cell Tumor (TGCT): An Update

  • Vasiliki Dania,
  • Nikolaos A. Stavropoulos,
  • Panayiotis Gavriil,
  • Ioannis Trikoupis,
  • Panagiotis Koulouvaris,
  • Olga D. Savvidou,
  • Andreas F. Mavrogenis and
  • Panayiotis J. Papagelopoulos

12 October 2024

Background and Objectives: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive, benign neoplasm arising from the synovium of joints, tendon sheaths, and bursa. There are two main subtypes of TGCT: localized-type TGCT(L-TGCT) and diffus...

  • Article
  • Open Access
1 Citations
2,378 Views
18 Pages

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

  • Hossein Taghizadeh,
  • Agnieszka Maj-Hes,
  • Gerald W. Prager,
  • Leonhard Müllauer and
  • Robert M. Mader

12 April 2022

In this analysis, we examined the efficacy, feasibility, and limitations of the application of mTOR inhibitors based on the individual molecular profiles of pretreated cancer patients after the failure of all standard treatments in the palliative set...

  • Article
  • Open Access
10 Citations
3,388 Views
14 Pages

Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study

  • Jun Sik Yoon,
  • Dong Hyun Sinn,
  • Jeong-Hoon Lee,
  • Hwi Young Kim,
  • Cheol-Hyung Lee,
  • Sun Woong Kim,
  • Hyo Young Lee,
  • Joon Yeul Nam,
  • Young Chang and
  • Yun Bin Lee
  • + 6 authors

4 November 2019

Background: For patients with hepatocellular carcinoma (HCC), the definition of refractoriness to transarterial chemoembolization (TACE), which might make them a candidate for systemic therapy, is still controversial. We aimed to derive and validate...

  • Article
  • Open Access
11 Citations
2,714 Views
11 Pages

Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial

  • Silvia Camera,
  • Tugba Akin Telli,
  • Erwin Woff,
  • Caroline Vandeputte,
  • Pashalina Kehagias,
  • Thomas Guiot,
  • Gabriela Critchi,
  • Yacine Wissam,
  • Giacomo Bregni and
  • Elena Trevisi
  • + 10 authors

24 September 2020

Introduction: Decision making in refractory colorectal cancer (rCRC) is challenging, with limited data available to predict patient outcome. We conducted a study to assess the pace of cancer progression as a potential prognostic and decision tool. Me...

  • Case Report
  • Open Access
1,644 Views
10 Pages

Challenges in the Treatment of a Refractory Testicular Germ Cell Tumor in Young Patients with Imminent Organ Failure—A Case Report

  • Iuliana Pantelimon,
  • Andra-Maria Stancu,
  • Claudiu Socoliuc,
  • Fikirie Abzait,
  • Irina Balescu,
  • Nicolae Bacalbasa,
  • Cristian Balalau,
  • Laurenţia Nicoleta Galeș and
  • Iulian Brezean

Background/Aim: This case report navigates through the challenges of a complex clinical scenario involving germ cell tumors (GCTs), one of the most frequently encountered malignancies in adolescents and young adults. Case report: We present the case...

  • Case Report
  • Open Access
1 Citations
1,514 Views
11 Pages

Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Pediatric Patients with Refractory or Recurrent High-Grade Gliomas: A Report of the Pediatric Brain Tumor Consortium

  • Aaron Y. Mochizuki,
  • Trent R. Hummel,
  • Timothy Cripe,
  • Maryam Fouladi,
  • Ian F. Pollack,
  • Duane Mitchell,
  • Tina Young Poussaint,
  • Arzu Onar-Thomas,
  • Natasha Pillay-Smiley and
  • Mariko DeWire-Schottmiller
  • + 1 author

26 December 2024

Background/Objectives: Multiple immune-modulatory strategies have been tested in efforts to mitigate the pro-tumor microenvironment in pediatric high-grade glioma. HSV1716 is an oncolytic virus that previously demonstrated evidence of response in adu...

  • Review
  • Open Access
23 Citations
5,164 Views
14 Pages

Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors

  • Ugo De Giorgi,
  • Chiara Casadei,
  • Alice Bergamini,
  • Laura Attademo,
  • Gennaro Cormio,
  • Domenica Lorusso,
  • Sandro Pignata and
  • Giorgia Mangili

17 October 2019

The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is oft...

  • Article
  • Open Access
21 Citations
6,532 Views
22 Pages

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

  • Christoph Schliemann,
  • Mirjam Gerwing,
  • Hauke Heinzow,
  • Saliha Harrach,
  • Christian Schwöppe,
  • Moritz Wildgruber,
  • Anna A. Hansmeier,
  • Linus Angenendt,
  • Andrew F. Berdel and
  • Ursula Stalmann
  • + 17 authors

7 June 2020

Background: Aminopeptidase N (CD13) is present on tumor vasculature cells and some tumor cells. Truncated tissue factor (tTF) with a C-terminal NGR-peptide (tTF-NGR) binds to CD13 and causes tumor vascular thrombosis with infarction. Methods: We trea...

  • Case Report
  • Open Access
1,901 Views
13 Pages

High Tumor Mutation Burden (TMB) and a Novel Somatic Mutation in the TREX1 Gene in a Patient with Aggressive and Refractory High-Grade B-Cell Lymphoma: A Case Report

  • Mariia Gusakova,
  • Fedor Sharko,
  • Eugenia Boulygina,
  • Natalia Slobodova,
  • Maria Gladysheva-Azgari,
  • Darima Badmazhapova,
  • Artem Bullikh,
  • Marina Khestanova,
  • Nelli Gabeeva and
  • Tatiana Obukhova
  • + 2 authors

High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a rare entity within the spectrum of B-cell lymphomas. HGBL, NOS remains a diagnosis of exclusion with limited data available on the optimal clinical approach. We report a case of a...

  • Article
  • Open Access
8 Citations
4,326 Views
7 Pages

Arthritis and Diagnostics in Lyme Disease

  • Javier A. Quintero,
  • Raluchukwu Attah,
  • Reena Khianey,
  • Eugenio Capitle and
  • Steven E. Schutzer

The diagnosis of Lyme disease, caused by Borrelia burgdorferi, is clinical but frequently supported by laboratory tests. Lyme arthritis is now less frequently seen than at the time of its discovery. However, it still occurs, and it is important to re...

  • Article
  • Open Access
5 Citations
2,905 Views
17 Pages

Association of Genetic and Allelic Variants of Von Willebrand Factor (VWF), Glutathione S-Transferase and Tumor Necrosis Factor Alpha with Ischemic Stroke Susceptibility and Progression in the Saudi Population

  • Mohammed M. Jalal,
  • Rashid Mir,
  • Abdullah Hamadi,
  • Malik A. Altayar,
  • Imadeldin Elfaki,
  • Jameel Barnawi,
  • Almohanad A. Alkayyal,
  • Mouminah Amr,
  • Jabali Hadeel and
  • Mamdoh S. Moawadh
  • + 3 authors

17 May 2023

Stroke is a key cerebrovascular disease and important cause of death and disability worldwide, including in the kingdom of Saudi Arabia (KSA). It has a large economic burden and serious socioeconomic impacts on patients, their families and the commun...

  • Article
  • Open Access
5 Citations
1,987 Views
16 Pages

Differential Expression of Serum Proinflammatory Cytokine TNF-α and Genetic Determinants of TNF-α, CYP2C19*17, miR-423 Genes and Their Effect on Coronary Artery Disease Predisposition and Progression

  • Rehab F. Almassabi,
  • Rashid Mir,
  • Jamsheed Javid,
  • Faisel M. AbuDuhier,
  • Reema Almotairi,
  • Marwan H. Alhelali,
  • Naseh Algehainy,
  • Basim S. O. Alsaedi,
  • Salem Owaid Albalawi and
  • Imadeldin Elfaki

31 October 2023

Coronary artery disease (CAD) is the leading cause of death and hospitalization worldwide and represents a problem for public health systems everywhere. In Saudi Arabia, the prevalence of CAD is estimated to be 5.5%. Risk factors for CAD include olde...

  • Article
  • Open Access
818 Views
19 Pages

A Novel Microfluidic Platform for Circulating Tumor Cell Identification in Non-Small-Cell Lung Cancer

  • Tingting Tian,
  • Shanni Ma,
  • Yan Wang,
  • He Yin,
  • Tiantian Dang,
  • Guangqi Li,
  • Jiaming Li,
  • Weijie Feng,
  • Mei Tian and
  • Jinbo Ma
  • + 1 author

1 October 2025

Circulating tumor cells (CTCs) are crucial biomarkers for lung cancer metastasis and recurrence, garnering significant clinical attention. Despite this, efficient and cost-effective detection methods remain scarce. Consequently, there is an urgent de...

  • Article
  • Open Access
5 Citations
3,064 Views
13 Pages

PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer

  • Leila Shobab,
  • Deema Al-Souri,
  • Liza Mathews-Kim,
  • Matthew McCoy,
  • William Kuenstner,
  • Gretchen K. Hubbard,
  • Sonam Kumari,
  • Jiling Chou,
  • Wen Lee and
  • Jennifer Rosen
  • + 5 authors

28 October 2024

Background: Thyroid cancer (TC) remains a significant clinical challenge worldwide, with a subset of patients facing aggressive disease progression and therapeutic resistance. Immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) h...

  • Article
  • Open Access
10 Citations
3,533 Views
11 Pages

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials

  • Davide Ciardiello,
  • Stefania Napolitano,
  • Vincenzo Famiglietti,
  • Lucia Esposito,
  • Vincenzo De Falco,
  • Alessandra Di Liello,
  • Antonio Avallone,
  • Evaristo Maiello,
  • Filippo Pietrantonio and
  • Chiara Cremolini
  • + 6 authors

1 April 2023

Rechallenge with anti-EGFR drugs represents a promising strategy in refractory RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC). We performed the pooled analysis of the CAVE and VELO studies to evaluate the percentage of patients with WT c...

  • Review
  • Open Access
4 Citations
3,868 Views
14 Pages

The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

  • Liliana Montella,
  • Margaret Ottaviano,
  • Rocco Morra,
  • Erica Pietroluongo,
  • Pietro De Placido,
  • Marianna Tortora,
  • Chiara Sorrentino,
  • Gaetano Facchini,
  • Sabino De Placido and
  • Mario Giuliano
  • + 1 author

2 February 2022

Thymic epithelial tumors are rare tumors usually presenting as a mass located in the anterior mediastinum and/or with symptoms deriving from associated paraneoplastic syndromes. Unresectable platinum-refractory tumors are often treated with alternati...

  • Article
  • Open Access
7 Citations
3,778 Views
15 Pages

APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma

  • Sarah Siraj,
  • Tariq Masoodi,
  • Abdul K. Siraj,
  • Saud Azam,
  • Zeeshan Qadri,
  • Sandeep K. Parvathareddy,
  • Rong Bu,
  • Khawar S. Siddiqui,
  • Saif S. Al-Sobhi and
  • Mohammed AlDawish
  • + 1 author

21 March 2022

Standard surgery followed by radioactive iodine (131I, RAI) therapy are not curative for 5–20% of papillary thyroid carcinoma (PTC) patients with RAI refractory disease. Early predictors indicating therapeutic response to RAI therapy in PTC are...

  • Review
  • Open Access
6 Citations
5,013 Views
18 Pages

Exportin 1 (XPO1) is a crucial molecule of nucleocytoplasmic transport. Among others, it exports molecules important for oncogenesis from the nucleus to the cytoplasm. The expression of XPO1 is increased in numerous malignancies, which contributes to...

  • Case Report
  • Open Access
5 Citations
4,265 Views
7 Pages

Targeted Therapy with Sirolimus and Nivolumab in a Child with Refractory Multifocal Anaplastic Ependymoma

  • Katia Perruccio,
  • Angela Mastronuzzi,
  • Marco Lupattelli,
  • Francesco Arcioni,
  • Ilaria Capolsini,
  • Carla Cerri,
  • Grazia M. I. Gurdo,
  • Maria Speranza Massei,
  • Elena Mastrodicasa and
  • Maurizio Caniglia

Pediatric ependymoma (EPN) is the third most common central nervous system (CNS) tumor, with 90% arising intracranially. Management typically involves maximal surgical resection and radiotherapy, but patients’ outcome is poor. Moreover, there are onl...

  • Article
  • Open Access
1 Citations
2,646 Views
15 Pages

A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors

  • S. Lindsey Davis,
  • Wells A. Messersmith,
  • W. Thomas Purcell,
  • Elaine T. Lam,
  • Bradley R. Corr,
  • Alexis D. Leal,
  • Christopher H. Lieu,
  • Cindy L. O’Bryant,
  • Stephen G. Smoots and
  • Evan D. Dus
  • + 4 authors

10 April 2024

Background: This study further evaluated the safety and efficacy of the combination of alisertib and sapanisertib in an expansion cohort of patients, including a subset of patients with refractory pancreatic adenocarcinoma, with further evaluation of...

  • Review
  • Open Access
1,607 Views
22 Pages

In the past decade, research on recombinant oncolytic viral agents in the treatment of solid tumors has evolved from the initial stage of simple genetic engineering to the current stage of multiple pipelines of parallel clinical application and combi...

  • Article
  • Open Access
9 Citations
2,787 Views
18 Pages

Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma

  • Seok-Mo Kim,
  • Keunwan Park,
  • Jin Hong Lim,
  • Hyeok Jun Yun,
  • Sang Yong Kim,
  • Kyung Hwa Choi,
  • Chan Wung Kim,
  • Jae Ha Lee,
  • Raymond Weicker and
  • Cheol-Ho Pan
  • + 1 author

8 September 2022

Thyroid carcinoma, a disease in which malignant cells form in the thyroid tissue, is the most common endocrine carcinoma, with papillary thyroid carcinoma (PTC) accounting for nearly 80% of total thyroid carcinoma cases. However, the management of me...

  • Review
  • Open Access
46 Citations
9,479 Views
16 Pages

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

  • María-Victoria Mateos,
  • Joan Bladé,
  • Sara Bringhen,
  • Enrique M Ocio,
  • Yvonne Efebera,
  • Luděk Pour,
  • Francesca Gay,
  • Pieter Sonneveld,
  • Joachim Gullbo and
  • Paul G. Richardson

27 September 2020

Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second l...

  • Review
  • Open Access
6 Citations
2,639 Views
10 Pages

Stereotactic Radiotherapy: An Alternative Option for Refractory Ventricular Tachycardia to Drug and Ablation Therapy

  • Wenfeng Shangguan,
  • Gang Xu,
  • Xin Wang,
  • Nan Zhang,
  • Xingpeng Liu,
  • Guangping Li,
  • Gary Tse and
  • Tong Liu

20 June 2022

Refractory ventricular tachycardia (VT) often occurs in the context of organic heart disease. It is associated with significantly high mortality and morbidity rates. Antiarrhythmic drugs and catheter ablation represent the two main treatment options...

  • Article
  • Open Access
3 Citations
4,785 Views
10 Pages

Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience

  • Miguel Cordova-Delgado,
  • Mauricio P. Pinto,
  • Carlos Regonesi,
  • Luis Cereceda,
  • José Miguel Reyes,
  • Laura Itriago,
  • Alejandro Majlis,
  • Pablo Rodríguez,
  • André Fassler and
  • Mauricio Mahave
  • + 8 authors

31 January 2022

Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and “biomarker-driven” treatments. However, the impact of this approach on the everyday cli...

  • Article
  • Open Access
9 Citations
2,258 Views
9 Pages

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors

  • Sophie L. Gerritse,
  • Mariette Labots,
  • Rob ter Heine,
  • Henk Dekker,
  • Dennis Poel,
  • Daniele V. F. Tauriello,
  • Iris D. Nagtegaal,
  • Erik Van Den Hombergh,
  • Nielka Van Erp and
  • Henk M. W. Verheul

9 December 2022

Patients with advanced cancer refractory to standard treatment were treated with sunitinib at a dose of 300 mg once every week (Q1W) or 700 mg once every two weeks (Q2W). Tumor, skin and plasma concentrations were measured and immunohistochemical sta...

  • Review
  • Open Access
30 Citations
12,942 Views
24 Pages

Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review

  • Asaf Maoz,
  • Koji Matsuo,
  • Marcia A. Ciccone,
  • Shinya Matsuzaki,
  • Maximilian Klar,
  • Lynda D. Roman,
  • Anil K. Sood and
  • David M. Gershenson

29 May 2020

Non-epithelial ovarian tumors are heterogeneous and account for approximately 10% of ovarian malignancies. The most common subtypes of non-epithelial ovarian tumors arise from germ cells or sex cord and stromal cells of the gonads. These tumors are u...

  • Review
  • Open Access
5 Citations
2,394 Views
21 Pages

30 May 2024

Glioblastoma (GBM) is the most common yet uniformly fatal adult brain cancer. Intra-tumoral molecular and cellular heterogeneities are major contributory factors to therapeutic refractoriness and futility in GBM. Molecular heterogeneity is represente...

  • Review
  • Open Access
28 Citations
5,997 Views
20 Pages

Epothilones as Natural Compounds for Novel Anticancer Drugs Development

  • Cecilia Villegas,
  • Iván González-Chavarría,
  • Viviana Burgos,
  • Héctor Iturra-Beiza,
  • Henning Ulrich and
  • Cristian Paz

Epothilone is a natural 16-membered macrolide cytotoxic compound produced by the metabolism of the cellulose-degrading myxobacterium Sorangium cellulosum. This review summarizes results in the study of epothilones against cancer with preclinical resu...

  • Review
  • Open Access
7 Citations
3,481 Views
22 Pages

22 May 2023

Thyroid cancer (TC) is the most common malignancy in the endocrine system. Although most TC can achieve a desirable prognosis, some refractory thyroid carcinomas, including radioiodine-refractory differentiated thyroid cancer, as well as anaplastic t...

  • Article
  • Open Access
2,708 Views
13 Pages

Tumor Growth Remains Refractory to Myc Ablation in Host Macrophages

  • Riley J. Morrow,
  • Amr H. Allam,
  • Josh Konecnik,
  • David Baloyan,
  • Christine Dijkstra,
  • Moritz F. Eissmann,
  • Saumya P. Jacob,
  • Megan O’Brien,
  • Ashleigh R. Poh and
  • Matthias Ernst

17 December 2022

Aberrant expression of the oncoprotein c-Myc (Myc) is frequently observed in solid tumors and is associated with reduced overall survival. In addition to well-recognized cancer cell-intrinsic roles of Myc, studies have also suggested tumor-promoting...

  • Article
  • Open Access
1 Citations
3,033 Views
11 Pages

16 April 2024

PV-10 is a 10% formulation of rose bengal sodium that has potent immunotherapeutic and anti-cancer activity against various tumors, including metastatic melanoma and refractory neuroblastoma. Currently, PV-10 is undergoing clinical testing for refrac...

  • Article
  • Open Access
7 Citations
3,339 Views
14 Pages

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma

  • Kei Amioka,
  • Tomokazu Kawaoka,
  • Takahiro Kinami,
  • Shintaro Yamasaki,
  • Masanari Kosaka,
  • Yusuke Johira,
  • Shigeki Yano,
  • Kensuke Naruto,
  • Yuwa Ando and
  • Yasutoshi Fujii
  • + 22 authors

16 October 2022

Transarterial chemoembolization (TACE) has been the standard treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC). However, with recent advances in systemic therapy and the emergence of the concept of TACE-refractory or -un...

  • Article
  • Open Access
20 Citations
4,150 Views
17 Pages

MiR-182-5p Modulates Prostate Cancer Aggressive Phenotypes by Targeting EMT Associated Pathways

  • Marilesia Ferreira Souza,
  • Ilce Mara Syllos Cólus,
  • Aline Simoneti Fonseca,
  • Valquíria Casanova Antunes,
  • Deepak Kumar and
  • Luciane Regina Cavalli

22 January 2022

Prostate cancer (PCa) is a clinically heterogeneous disease, where deregulation of epigenetic events, such as miRNA expression alterations, are determinants for its development and progression. MiR-182-5p, a member of the miR-183 family, when overexp...

  • Article
  • Open Access
40 Citations
5,535 Views
12 Pages

Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer

  • Akane Sugimura-Nagata,
  • Akira Koshino,
  • Satoshi Inoue,
  • Aya Matsuo-Nagano,
  • Masayuki Komura,
  • Miho Riku,
  • Hideaki Ito,
  • Akihito Inoko,
  • Hideki Murakami and
  • Masahide Ebi
  • + 6 authors

Despite the confirmed anti-cancer effects of T-cell immune checkpoint inhibitors, in colorectal cancer (CRC) they are only effective in a small subset of patients with microsatellite-unstable tumors. Thus, therapeutics targeting other types of CRCs o...

of 17